707 / 1835
Duration of Response
in
90
Y Ibritumomab Tiuxetan Trials
Phase I-II
Phase II
Phase III
n
= 51
n
= 30
n
= 73
Overall Response, %
73
83
80
Median DR, months
11.7
11.5
13.9
CR/CRu, %
29*
47
34
Median DR, months
28*
23
23
Ongoing CR/CRu, %
19
14
32
Median DR, months
62.1
41.2
42.2
Range
60+ to 66+
40+ to 42+
33+ to 48+
Gordon et al. Blood 2004.
*Patients with CR only.